Insights

Clinical momentum Mestag is advancing a first-in-class fibroblast immunology pipeline with lead program MST-0312 entering clinical development in mid-2026 and ongoing Phase 1 STARLYS trial, signaling imminent engagement opportunities for CROs, trial logistics partners, and regulatory consultants.

Strategic governance Recent board appointments in the UK to strengthen clinical, regulatory, and strategic oversight indicate a heightened focus on global expansion, partnering, and potential collaboration with multinational stakeholders in oncology and inflammatory diseases.

Funding runway With a $53M funding base and a first clinical program nearing execution, there is appetite for strategic investors or grant collaborations, as well as consulting and capital-raising support for later-stage development and global trials.

Clinical leadership New executive hiring including Chief Medical Officer and Chief Development Officer highlights a readiness to scale operations, clinical program management, and regulatory strategy—opportunities for medical affairs partnerships, advisory roles, and clinical ops outsourcing.

Market positioning Targeting inflammatory disease and cancer via LTBR-focused bispecific antibodies positions Mestag in a high-need, biotech-dense space with potential buyers and licensees among mid to late-stage biotechs and pharma companies seeking novel immunology targets.

Similar companies to Mestag Therapeutics

Mestag Therapeutics Tech Stack

Mestag Therapeutics uses 8 technology products and services including Amazon Web Services, Open Graph, WordPress, and more. Explore Mestag Therapeutics's tech stack below.

Media & News

Mestag Therapeutics's Email Address Formats

Mestag Therapeutics uses at least 4 email formats:
Mestag Therapeutics Email FormatsExamplePercentage
FLast@mestagtx.comJDoe@mestagtx.com
91%
LastFirst@mestagtx.comDoeJohn@mestagtx.com
4%
F-Last@mestagtx.comJ-Doe@mestagtx.com
3%
First.Last@mestagtx.comJohn.Doe@mestagtx.com
2%

Frequently Asked Questions

What is Mestag Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Mestag Therapeutics's official website is mestagtherapeutics.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Mestag Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Mestag Therapeutics's annual revenue is estimated to be $1M - $10M.

What is Mestag Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Mestag Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mestag Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Mestag Therapeutics has approximately 40 employees across 2 continents, including Europe and North America. Key team members include Chief Business Officer: R. D. J., Chief Development Officer (cdo): P. M. and Chief Medical Officer: L. R. Explore Mestag Therapeutics's employee directory with LeadIQ.

What industry does Mestag Therapeutics belong to?

Minus sign iconPlus sign icon
Mestag Therapeutics operates in the Biotechnology Research industry.

What technology does Mestag Therapeutics use?

Minus sign iconPlus sign icon
Mestag Therapeutics's tech stack includes Amazon Web Services, Open Graph, WordPress, Cookiebot, Google Cloud, WP Engine, Smartsheet and BambooHR.

What is Mestag Therapeutics's email format?

Minus sign iconPlus sign icon
Mestag Therapeutics's email format typically follows the pattern of FLast@mestagtx.com. Find more Mestag Therapeutics email formats with LeadIQ.

How much funding has Mestag Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Mestag Therapeutics has raised $53M in funding. The last funding round occurred on Mar 17, 2026 for $2M.

When was Mestag Therapeutics founded?

Minus sign iconPlus sign icon
Mestag Therapeutics was founded in 2020.
Mestag Therapeutics logo

Mestag Therapeutics

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Mestag Therapeutics, based in London, England, focuses on the interactions between fibroblasts and the immune system to develop treatments for inflammatory diseases and cancer. By applying insights from fibroblast immunology, the company is developing a pipeline of first-in-class antibody programs and targets for novel therapies. As a small to mid-sized biotechnology firm, Mestag collaborates with global partners to identify therapeutic targets in its areas of focus.

In 2026, the company reported progress toward clinical development of its lead program MST-0312. It has collaborations with Johnson & Johnson and MSD to identify targets in inflammatory diseases, and it participates in scientific conferences to share its work.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
11-50

Section iconFunding & Financials

  • $53M

    Mestag Therapeutics has raised a total of $53M of funding over 3 rounds. Their latest funding round was raised on Mar 17, 2026 in the amount of $2M as a Venture Round.

  • $1M - $10M

    Mestag Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.